Academic Journal
Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect Comparison
| Title: | Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect Comparison |
|---|---|
| Authors: | David Cherney, Kerstin Folkerts, Paul Mernagh, Mateusz Nikodem, Joerg Pawlitschko, Peter Rossing, Neil Hawkins |
| Source: | Journal of Market Access & Health Policy, Vol 12, Iss 3, Pp 169-180 (2024) |
| Publisher Information: | MDPI AG, 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Public aspects of medicine LCC:Business |
| Subject Terms: | chronic kidney disease (CKD), type 2 diabetes (T2D), finerenone, canagliflozin, sodium glucose cotransporter 2 inhibitors (SGLT2i), matching-adjusted indirect comparison (MAIC), Public aspects of medicine, RA1-1270, Business, HF5001-6182 |
| More Details: | This study aimed to close an evidence gap concerning the relative efficacy of finerenone versus SGLT2is in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Canagliflozin was selected as a proxy for the SGLT2i class. Patient-level data of two randomized controlled trials (RCTs) of finerenone (FIDELIO-DKD and FIGARO-DKD) were used alongside aggregated data from CREDENCE, an RCT of canagliflozin. To account for meaningful between-study heterogeneity between each finerenone trial and CREDENCE, a matching-adjusted indirect comparison of a range of efficacy outcomes was undertaken for each finerenone study versus CREDENCE. These results were meta-analyzed, enabling the estimation of the relative effects of finerenone against canagliflozin. For the cardiorenal composite endpoint, the hazard ratio (HR) comparing finerenone to canagliflozin was 1.07 (95% CI: 0.83 to 1.36). The corresponding HRs for all-cause mortality, end-stage kidney disease and cardiovascular death were 0.99 (95% CI: 0.73 to 1.34), 1.03 (95% CI: 0.68 to 1.55) and 0.94 (95% CI: 0.64 to 1.37), respectively. The absence of statistically significant differences was consistent throughout the main analysis and a range of sensitivity analyses. Based on this study, using a large sample of data and adjusted for meaningful differences between the baseline characteristics of the included RCTs, there was no statistically significant evidence indicating a difference in the efficacy of finerenone compared to canagliflozin in the treatment of CKD in patients with T2D. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2001-6689 |
| Relation: | https://www.mdpi.com/2001-6689/12/3/14; https://doaj.org/toc/2001-6689 |
| DOI: | 10.3390/jmahp12030014 |
| Access URL: | https://doaj.org/article/dff937541dc9404db1fe3b6590a96398 |
| Accession Number: | edsdoj.ff937541dc9404db1fe3b6590a96398 |
| Database: | Directory of Open Access Journals |
| Full text is not displayed to guests. | Login for full access. |
| ISSN: | 20016689 |
|---|---|
| DOI: | 10.3390/jmahp12030014 |
| Published in: | Journal of Market Access & Health Policy |
| Language: | English |